A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

StatusCompleted
PhasePhase 1
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 7 entries Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 3, 2026
    • Eligibility criteria expanded, about 6 words
    • Site details revised
  2. Enrollment closed, study ongoing
    • Primary and study completion pushed from Jul 2026 to Sep 2026
    • Start date changed from estimate of May 5, 2026 to May 7, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
349 trials monitored
See 27 trials at risk
The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
Trial Details
NCT Number NCT07599761
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Healthy Volunteers
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov